BCTX - BriaCell selected to present at upcoming medical event; updates on buyback program

BriaCell Therapeutics (NASDAQ:BCTX) announced on Thursday that the company was selected to perform a presentation on off-the-shelf cancer therapies at the American Association for Cancer Research (AACR) Annual Meeting 2022, scheduled to be held in April. The presentation titled, “Towards a personalized off-the-shelf cellular immunotherapy for cancer” will be conducted on Apr. 22. In addition, BriaCell (BCTX) updated on its previously announced corporate buyback program, under which it plans to purchase up to ~1.3M common shares and ~411.9K publicly-traded BCTXW Listed Warrants indicating 10% of its public float as of Sept. 08. According to the latest data, BriaCell (BCTX) has repurchased ~1.0M common shares and ~200.7K publicly-traded BCTXW warrants, leaving ~14.0M and ~3.9M common shares and Listed Warrants outstanding in the public float, respectively. As previously announced, BriaCell (BCTX) also reiterated the intention of certain members of its board and the management to purchase nearly 10% of Common Shares and Listed

For further details see:

BriaCell selected to present at upcoming medical event; updates on buyback program